These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38543552)

  • 61. SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
    Walker SN; Chokkalingam N; Reuschel EL; Purwar M; Xu Z; Gary EN; Kim KY; Helble M; Schultheis K; Walters J; Ramos S; Muthumani K; Smith TRF; Broderick KE; Tebas P; Patel A; Weiner DB; Kulp DW
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32855181
    [No Abstract]   [Full Text] [Related]  

  • 62. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
    Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines.
    Hvidt AK; Baerends EAM; Søgaard OS; Stærke NB; Raben D; Reekie J; Nielsen H; Johansen IS; Wiese L; Benfield TL; Iversen KK; Mustafa AB; Juhl MR; Petersen KT; Ostrowski SR; Lindvig SO; Rasmussen LD; Schleimann MH; Andersen SD; Juhl AK; Dietz LL; Andreasen SR; Lundgren J; Østergaard L; Tolstrup M;
    Front Med (Lausanne); 2022; 9():994160. PubMed ID: 36262278
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
    Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
    Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.
    Sutandhio S; Furukawa K; Kurahashi Y; Marini MI; Effendi GB; Hasegawa N; Ishimaru H; Nishimura M; Arii J; Mori Y
    J Infect Public Health; 2023 Jul; 16(7):1064-1072. PubMed ID: 37196370
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
    Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
    Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
    Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
    Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
    Madhi SA; Moodley D; Hanley S; Archary M; Hoosain Z; Lalloo U; Louw C; Fairlie L; Fouche LF; Masilela MSL; Singh N; Grobbelaar C; Ahmed K; Benadé G; Bhikha S; Bhorat AE; Bhorat Q; Joseph N; Dheda K; Esmail A; Foulkes S; Goga A; Oommen Jose A; Kruger G; Kalonji DJ; Lalloo N; Lombaard JJ; Lombard Koen A; Kany Luabeya A; Mngqibisa R; Petrick FG; Pitsi A; Tameris M; Thombrayil A; Vollgraaff PL; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Fries L; Robertson A; Neal S; Cho I; Glenn GM; Shinde V;
    Lancet HIV; 2022 May; 9(5):e309-e322. PubMed ID: 35489376
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody.
    Li Y; He J; Zhang Y; Liang D; Zhang J; Ji R; Wu Y; Su Z; Ke C; Xu N; Tang Y; Xu J
    Front Cell Infect Microbiol; 2023; 13():1203625. PubMed ID: 37736103
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
    Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
    Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants.
    Lusvarghi S; Stauft CB; Vassell R; Williams B; Baha H; Wang W; Neerukonda SN; Wang T; Weiss CD
    PLoS Pathog; 2023 Nov; 19(11):e1011788. PubMed ID: 37943965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
    Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter.
    Suzuki R; Kamiyama A; Ito H; Kawashiro K; Tomiyama T; Tamura T; Suzuki S; Yoshizumi T; Hotta K; Fukuhara T
    J Virol Methods; 2024 May; 326():114894. PubMed ID: 38360268
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.
    Salazar-García M; Acosta-Contreras S; Rodríguez-Martínez G; Cruz-Rangel A; Flores-Alanis A; Patiño-López G; Luna-Pineda VM
    Front Microbiol; 2021; 12():817200. PubMed ID: 35095820
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept.
    Cruz-Cardenas JA; Gutierrez M; López-Arredondo A; Castañeda-Delgado JE; Rojas-Martinez A; Nakamura Y; Enciso-Moreno JA; Palomares LA; Brunck MEG
    Sci Rep; 2022 Oct; 12(1):17966. PubMed ID: 36289285
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.
    Thimmiraju SR; Villar MJ; Kimata JT; Strych U; Bottazzi ME; Hotez PJ; Pollet J
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.